Clinical Trials Logo

Radiation Proctitis clinical trials

View clinical trials related to Radiation Proctitis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05489107 Recruiting - Radiation Proctitis Clinical Trials

New Local Treatment of Radiation-induced Proctitis

NOTRIP
Start date: July 1, 2022
Phase:
Study type: Observational

A prospective single-center observational study to evaluate the effectiveness of a local treatment with a mixture of hyaluronic acid, chondroitin sulfate and poloxamer 407 in patients with radiation-induced proctitis.

NCT ID: NCT05406882 Recruiting - Gut Microbiota Clinical Trials

The Effects of Probiotics Combined With Glutamine in the Prevention and Treatment of Radiation Proctitis

Start date: April 15, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Radiation proctitis is a common complication after radiation therapy for pelvic tumors. The investigators found that live bifidobacterium and lactobacillus tablets combined with compound glutamine enteric-coated capsules can significantly relieve the symptoms of radiation proctitis through preliminary clinical practice, but the mechanism is unknown. Through a prospective randomized controlled study, this study intends to investigate the incidence of grade 2 or higher acute radiation proctitis in patients of locally advanced rectal cancer after radiotherapy with the combined therapy. And through various scales, next-generation sequencing methods and other methods to evaluate the clinical symptoms, colonoscopy, imaging, and changes in the species and abundance of intestinal flora before and after treatment. To further explore the related pathways and mechanisms affecting radiation proctitis.

NCT ID: NCT01414517 Recruiting - Radiation Enteritis Clinical Trials

Study to Prevent Radiation Induced Damage to Bowel Using a Prebiotic Enhanced Diet.

Start date: August 2010
Phase: Phase 3
Study type: Interventional

The study will consist of pair of double-blind placebo-controlled trials of dietary supplementation with 15g/day FructoOligoSaccharide (FOS) for 7.5 weeks in patients with prostate carcinoma or 5 weeks in patients with cervical or endometrial carcinoma who are to undergo pelvic radiotherapy with intent to cure.